Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;20(8):1387-96.
doi: 10.1007/s10552-009-9365-4. Epub 2009 May 29.

Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination

Richard A Moore  1 , Gina Ogilvie, Daniel Fornika, Veronika Moravan, Marc Brisson, Mahsa Amirabbasi-Beik, Anita Kollar, Thomas Burgess, Ray Hsu, Laura Towers, Jane Lo, Jasenka Matisic, Angela Brooks-Wilson
Affiliations

Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination

Richard A Moore et al. Cancer Causes Control. 2009 Oct.

Abstract

Background: Human papilloma virus (HPV) prevalence studies performed in different regions and population groups across Canada would inform public health decisions regarding implementation of anti-HPV vaccines.

Methods: A total of 8,700 liquid-based specimens from 8,660 women aged 13-86 from throughout British Columbia were collected. DNA was isolated from 4,980 of these samples and assessed for HPV prevalence and type distribution. HPV was detected by PCR analysis using tagged GP5+/6+ consensus primers to amplify the L1 region of HPV; typing was done by bi-directional sequencing of PCR products.

Results: Overall HPV prevalence was 16.8% (age adjusted 15.5%). Prevalence of high-risk HPV was 13.9, and 10.7% of samples contained HPV16. HPV prevalence was highest in the youngest group of women (<20 years). One-third of HPV positive samples contained more than one HPV type. Percentages of low-grade (LGIL) and high-grade intraepithelial lesions (HGIL) containing high-risk HPV are 52.3 and 79.4%, respectively.

Conclusions: Overall HPV prevalence in this study is within the range of estimates from other studies. The prevalence of HPV16 is higher than what is found in other Canadian and international studies. HPV16 and HPV18 compose a majority of the high-risk virus in this study. Use of current HPV vaccines could considerably reduce HPV-related conditions including cervical cancer and procedures such as colposcopy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Prevalence of individual HPV types and categories by cytology. Data are not adjusted for ages. 95% confidence intervals are shown
Fig. 2
Fig. 2
HPV prevalence by 5-year age strata. 95% Confidence intervals are shown. In BC, cervical cancer screening is not recommended for women over 70, so those over 70 in this sample represent a nonrandom set of women who likely presented with symptoms and for whom cytology was conducted as part of a diagnostic work-up
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F', 'is_inner': False, 'url': 'https://doi.org/10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f'}, {'type': 'PubMed', 'value': '10451482', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10451482/'}]}
    2. Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1086/425907', 'is_inner': False, 'url': 'https://doi.org/10.1086/425907'}, {'type': 'PubMed', 'value': '15551205', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15551205/'}]}
    2. Munoz N, Mendez F, Posso H et al (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190:2077–2087. doi:10.1086/425907 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(04)17398-4', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(04)17398-4'}, {'type': 'PubMed', 'value': '15541448', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15541448/'}]}
    2. Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765. doi:10.1016/S0140-6736(04)17398-4 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(06)68439-0', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(06)68439-0'}, {'type': 'PubMed', 'value': '16631880', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16631880/'}]}
    2. Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255. doi:10.1016/S0140-6736(06)68439-0 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJMoa020586', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejmoa020586'}, {'type': 'PubMed', 'value': '12444178', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12444178/'}]}
    2. Koutsky LA, Ault KA, Wheeler CM et al (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651. doi:10.1056/NEJMoa020586 - PubMed

Publication types

MeSH terms

LinkOut - more resources